As TIM-3 is associated with reduced T cell effector function, and as we observed changes in the percentage of TIM-3 positivity on CD4+ and CD8+ T cells and NK cells from glioblastoma patients, we next evaluated the activation statuses of these T cell subsets and NK cells. The gene discussed is CD8A; the disease is glioblastoma.